CAJ | 학술논문

本文综述了瑞戈非尼治疗结肠直肠癌和胃肠道间质瘤的药理、药动学、临床研究和安全性信息。主要参考国外有关的瑞格菲尼的注册和临床资料。临床试验表明瑞戈非尼能使患者的总生存期、无进展生存期获得明显提高。接受治疗的患者中最严重的药物不良反应是严重肝损伤、出血和胃肠道穿孔，最常见的不良反应（≥30%）为虚弱／疲乏、食欲减退、食物摄入量减少、手足皮肤反应、腹泻、消瘦、高血压和发音障碍。
본문종술료서과비니치료결장직장암화위장도간질류적약리、약동학、림상연구화안전성신식。주요삼고국외유관적서격비니적주책화림상자료。림상시험표명서과비니능사환자적총생존기、무진전생존기획득명현제고。접수치료적환자중최엄중적약물불량반응시엄중간손상、출혈화위장도천공，최상견적불량반응（≥30%）위허약／피핍、식욕감퇴、식물섭입량감소、수족피부반응、복사、소수、고혈압화발음장애。
Pharmacology,pharmacokinetics,clinical study and safety of regorafenib in the treatment of colorectal cancer and gastrointestinal stromal tumors were reviewed in the paper. The main refeience to foreign - related registration and clini-cal data of regorafenib. Clinical trials showed the Overall Survival(OS)and Progression - Free - Survival(PFS)was sig-nificantly increased in patients treated with regorafenib. The most serious adverse drug reactions in patients receiving Stivar-ga were severe liver injury,haemorrhage and gastrointestinal perforation. The most frequently observed adverse drug reactions (≥30% )in patients receiving Stivarga were asthenia/ fatigue,decreased appetite and food intake,hand foot skin reaction, diarrhoea,weight loss,hypertension and dysphonia.